Employing epigenetics to augment the expression of therapeutic proteins in mammalian cells.
Recombinant proteins form an increasingly large part of the portfolio of biopharmaceutical companies. Production of these often complex transgenic proteins is achieved predominantly in mammalian cell lines but the process is hampered by low yields and unstable expression. Some of these problems are caused by gene silencing at the level of chromatin - so-called epigenetic gene silencing. Here, we describe approaches, which have emerged during the past few years, designed to interfere with epigenetic gene silencing with the aim of enhancing and stabilizing transgene expression. These include targeting histones, the inclusion of specific DNA elements and targeting sites of high gene-expression. We conclude that employing epigenetic gene regulation tools, in combination with further process optimization, might represent the next step forward in the production of therapeutic proteins.
Kwaks
Ted H J
TH
ChromaGenics, Kruislaan 406, 1098 SM, Amsterdam, The Netherlands.
Otte
Arie P
AP
D000818:Animals; D002843:Chromatin / Q000235:genetics*; D044127:Epigenesis, Genetic / Q000235:genetics*; D020868:Gene Silencing; D018390:Gene Targeting / Q000379:methods / Q000639:trends; D005818:Genetic Engineering / Q000379:methods / Q000639:trends; D006801:Humans; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000627:therapeutic use
D002843:Chromatin; D011994:Recombinant Proteins